KemPharm Reports First Quarter 2021 Financial Results
Corporate and Regulatory Highlights AZSTARYSTM NDA approved by the FDA on March 2, 2021Announced amendment to Licensing Agreement with Gurnet Point Capital affiliate following FDA approval of AZSTARYSReceived FDA clearance to initiate KP879 clinical program for the treatment of Stimulant Use DisorderSerdexmethylphenidate (SDX) classified as a Schedule IV Controlled Substance by the DEA Financial Highlights Completed financial restructuring, which resulted in re-listing on The Nasdaq Capital Market, receipt of approximate gross proceeds of $94 million and no debtReported Q1 2021 revenue of $12.1 millionQ1 2021 net loss of ($0.54) per basic share and diluted share compared to a net lo
